European Medicines Agency decision
P/0046/2013

of 1 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver for obinutuzumab (EMEA-001207-PIP01-11) in accordance with Regulation (EC)

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of

Only the English text is authentic.
European Medicines Agency decision
P/0046/2013

of 1 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver for obinutuzumab (EMEA-001207-PIP01-11) in accordance with Regulation (EC)

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of
12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC)

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of
31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal
products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Roche Registration Limited on 7 November 2011 under
Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said
Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on
11 January 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said
Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the
agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for obinutuzumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for obinutuzumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for obinutuzumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to Roche Registration Limited, 6 Falcon Way, Shire Park, AL7 1TW Welwyn Garden City, United Kingdom.

Done at London, 1 March 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver
EMEA-001207-PIP01-11

Scope of the application

Active substance(s):
Obinutuzumab

Condition(s):
Treatment of mature B-cell lymphoma
Treatment of acute lymphoblastic leukaemia

Pharmaceutical form(s):
Concentrate for solution for infusion

Route(s) of administration:
Intravenous use

Name/corporate name of the PIP applicant:
Roche Registration Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Roche Registration Limited submitted for agreement to the European Medicines Agency on 7 November 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 14 December 2011.
Supplementary information was provided by the applicant on 22 October 2012. The applicant proposed modifications to the paediatric investigation plan.

**Opinion**

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 11 January 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

1.1. **Condition: Treatment of mature B-cell lymphoma and acute lymphoblastic leukaemia**

The waiver applies to:

- The paediatric population from birth to less than 6 months of age
- for concentrate for solution for infusion for intravenous use
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. **Condition: Treatment of mature B-cell lymphoma and acute lymphoblastic leukaemia**

2.1.1. **Indication(s) targeted by the PIP**

Treatment of children and adolescents with previously untreated mature B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukaemia in combination with chemotherapy

2.1.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From 6 months to less than 18 years of age

2.1.3. **Pharmaceutical form(s)**

Concentrate for solution for infusion for intravenous use

2.1.4. **Measures**

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>0</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>1</td>
<td>Measure 1: Enhanced pre- and postnatal development study</td>
</tr>
<tr>
<td>Clinical</td>
<td>1</td>
<td>Measure 2: Open-label, two-stage, randomised, active-controlled trial to evaluate the safety and efficacy of obinutuzumab compared to rituximab as part of a multi-agent chemotherapy regimen in children with mature B-cell lymphoma from 6 months to less than 18 years of age</td>
</tr>
</tbody>
</table>

3. Follow-up, completion and deferral of PIP

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concerns on potential long term safety issues in relation to paediatric use:</td>
<td></td>
</tr>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By June 2024</td>
</tr>
<tr>
<td>Deferral for one or more measures contained in the paediatric investigation plan:</td>
<td>Yes</td>
</tr>
</tbody>
</table>